Immune Regulation News Volume 3.20 | Jun 3 2011

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Stimulating an immune response against cancer with the use of vaccines remains a challenge. Researchers hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes. [New Engl J Med]

Autoantigen Discovery with a Synthetic Human Peptidome
Here researchers present a synthetic representation of the complete human proteome, the T7 peptidome phage display library, and demonstrate its application to autoantigen discovery. [Nat Biotechnol]

Innate Lymphoid Cells Mediate Influenza-Induced Airway Hyper-Reactivity Independently of Adaptive Immunity
Researchers show here in a mouse model that influenza infection acutely induced airway hyper-reactivity, a cardinal feature of asthma, independently of T helper type 2 cells and adaptive immunity. [Nat Immunol]

Transcription Factor T-bet Represses Expression of the Inhibitory Receptor PD-1 and Sustains Virus-Specific CD8+ T Cell Responses during Chronic Infection
Here researchers demonstrate that the transcription factor T-bet regulated the exhaustion of CD8+ T cells and the expression of inhibitory receptors. [Nat Immunol]

ICOS Receptor Instructs T Follicular Helper Cell versus Effector Cell Differentiation via Induction of the Transcriptional Repressor Bcl6
Here researchers determine that follicular helper CD4+ T cell development initiates immediately during dendritic cell priming in vivo. [Immunity]

Germinal Center B Cell and T Follicular Helper Cell Development Initiates in the Interfollicular Zone
Researchers identify the interfollicular zone as the site where germinal center B cell and T follicular helper cell differentiation initiates. [Immunity]

Bcl6 Protein Expression Shapes Pre-Germinal Center B Cell Dynamics and Follicular Helper T Cell Heterogeneity
By using a Bcl6 reporter mouse strain, researchers found that antigen-engaged B cells upregulated Bcl6 before clustering in germinal centers. [Immunity]

CCL17-Expressing Dendritic Cells Drive Atherosclerosis by Restraining Regulatory T Cell Homeostasis in Mice
Researchers have shown that the dendritic cell (DC)-derived chemokine CCL17 is present in advanced human and mouse atherosclerosis and that CCL17+ DCs accumulate in atherosclerotic lesions. [J Clin Invest]

Attenuation of HIV-Associated Human B Cell Exhaustion by siRNA Downregulation of Inhibitory Receptors
Here, researchers show that downregulation of B cell inhibitory receptors in primary human B cells led to increased tissue-like memory B cell proliferation and responsiveness against HIV. [J Clin Invest]

Induction of Regulatory T Cells by Green Tea Polyphenol EGCG
Researchers showed that EGCG, a major green tea polyphenol, could act as a dietary DNA methyltransferase inhibitor, and induced Foxp3 and IL-10 expression in CD4+ Jurkat T cells at physiologically relevant concentrations in vitro. [Immunol Lett]

Argos Therapeutics’ Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination with Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Argos Therapeutics announced that its Arcelis^TM immunotherapy for the treatment of RCC, AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. [Argos Therapeutics Press Release]

TxCell Treats First Patient in Maintenance Phase of CATS1 Study for Patients with Crohn’s Disease who Benefited from Ovasave
TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces the treatment of the first patient in the long term maintenance phase of CATS1 study. [TxCell Press Release]

Opexa Initiates Discussions with Health Canada in Pre-CTA Meeting
Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis, announced that the Company met this week with Health Canada’s Biologics and Genetics Therapies Directorate, in a pre-Clinical Trial Application (pre-CTA) meeting. [Opexa Therapeutics, Inc. Press Release]

Immunovaccine Announces Immune Results from Phase I Trial for DPX-0907 Therapeutic Cancer Vaccine
Immunovaccine Inc. announced the completion of a detailed analysis of immune responses from patients enrolled in the Phase I clinical trial assessing the safety and tolerability of DPX-0907, a therapeutic cancer vaccine. [Immunovaccine Inc. Press Release]

Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Anthera Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock, offered at a price of $7.50 per share. [Anthera Pharmaceuticals, Inc. Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 4th International Conference on Crossroads between Innate and Adaptive Immunity
September 11-16, 2011
Mykonos, Greece

Visit our events page to see a complete list of events in the immune regulation community.

Chemist (STEMCELL Technologies)

Lab Technologist – Cell Separation (STEMCELL Technologies)

Research and Development Senior Technologist (STEMCELL Technologies)

Proteomics, Vascular Biology/Angiogenesis, or Immunology (St.Michael’s Hospital/University of Toronto)

Research Scientist in Immunology (Nestle Research Center)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.